The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2021 | The impact of obesity on OS in MDS patients
Rami Komrokji, MD, of the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, talks on the impact of obesity on the overall survival (OS) of patients with myelodysplastic syndromes (MDS). A retrospective study used body mass index (BMI) data to determine a correlation between obesity (a BMI greater than 30) and OS amongst patients with MDS. It was found that a BMI greater than 30 leads to an inferior OS in patients with low-risk MDS and in patients that were aged less than 65 years. Dr Komrokji explains that the unclear relationship between high-risk MDS and obesity was perhaps owed to the interplay of the comorbidities present. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
